补充硫胺素在治疗慢性心力衰竭中的作用：随机对照试验的最新元分析》。

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-06-28 DOI:10.1002/clc.24309

Shuai He, Shasha Wang, Tingli Xu, Shuwei Wang, Minfang Qi, Qingqing Chen, Lu Lin, Huijuan Wu, Pengcheng Gan

{"title":"补充硫胺素在治疗慢性心力衰竭中的作用：随机对照试验的最新元分析》。","authors":"Shuai He, Shasha Wang, Tingli Xu, Shuwei Wang, Minfang Qi, Qingqing Chen, Lu Lin, Huijuan Wu, Pengcheng Gan","doi":"10.1002/clc.24309","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Chronic heart failure (CHF) has always posed a significant threat to human survival and health. The efficacy of thiamine supplementation in CHF patients remains uncertain.</p>\n </section>\n \n <section>\n \n <h3> Hypothesis</h3>\n \n <p>Receiving supplementary thiamine may not confer benefits to patients with CHF.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A comprehensive search was conducted across the Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov, and Web of Science databases up until May 2023 to identify articles investigating the effects of thiamine supplementation in CHF patients. Predefined criteria were utilized for selecting data on study characteristics and results.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Seven randomized, double-blind, controlled trials (five parallel trials and two crossover trials) involving a total of 274 patients were enrolled. The results of the meta-analysis pooling these studies did not reveal any significant effect of thiamine treatment compared with placebo on left ventricular ejection fraction (WMD = 1.653%, 95% CI: −1.098 to 4.405, <i>p</i> = 0.239, <i>I</i><sup>2</sup> = 61.8%), left ventricular end-diastolic volume (WMD = −6.831 mL, 95% CI: −26.367 to 12.704, <i>p</i> = 0.493, <i>I</i><sup>2</sup> = 0.0%), 6-min walking test (WMD = 16.526 m, 95% CI: −36.582 to 69.634, <i>p</i> = 0.542, <i>I</i><sup>2</sup> = 66.3%), N-terminal pro-B type natriuretic peptide (WMD = 258.150 pg/mL, 95% CI: −236.406 to 752.707, <i>p</i> = 0.306, <i>I</i><sup>2</sup> = 21.6%), or New York Heart Association class (WMD = −0.223, 95% CI: −0.781 to 0.335, <i>p</i> = 0.434, <i>I</i><sup>2</sup> = 87.1%). However, it effectively improved the status of thiamine deficiency (TD).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our meta-analysis indicates that thiamine supplementation does not have a direct therapeutic effect on CHF, except for correcting TD.</p>\n </section>\n </div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212003/pdf/","citationCount":"0","resultStr":"{\"title\":\"Role of Thiamine Supplementation in the Treatment of Chronic Heart Failure: An Updated Meta-Analysis of Randomized Controlled Trials\",\"authors\":\"Shuai He, Shasha Wang, Tingli Xu, Shuwei Wang, Minfang Qi, Qingqing Chen, Lu Lin, Huijuan Wu, Pengcheng Gan\",\"doi\":\"10.1002/clc.24309\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Chronic heart failure (CHF) has always posed a significant threat to human survival and health. The efficacy of thiamine supplementation in CHF patients remains uncertain.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Hypothesis</h3>\\n \\n <p>Receiving supplementary thiamine may not confer benefits to patients with CHF.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A comprehensive search was conducted across the Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov, and Web of Science databases up until May 2023 to identify articles investigating the effects of thiamine supplementation in CHF patients. Predefined criteria were utilized for selecting data on study characteristics and results.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Seven randomized, double-blind, controlled trials (five parallel trials and two crossover trials) involving a total of 274 patients were enrolled. The results of the meta-analysis pooling these studies did not reveal any significant effect of thiamine treatment compared with placebo on left ventricular ejection fraction (WMD = 1.653%, 95% CI: −1.098 to 4.405, <i>p</i> = 0.239, <i>I</i><sup>2</sup> = 61.8%), left ventricular end-diastolic volume (WMD = −6.831 mL, 95% CI: −26.367 to 12.704, <i>p</i> = 0.493, <i>I</i><sup>2</sup> = 0.0%), 6-min walking test (WMD = 16.526 m, 95% CI: −36.582 to 69.634, <i>p</i> = 0.542, <i>I</i><sup>2</sup> = 66.3%), N-terminal pro-B type natriuretic peptide (WMD = 258.150 pg/mL, 95% CI: −236.406 to 752.707, <i>p</i> = 0.306, <i>I</i><sup>2</sup> = 21.6%), or New York Heart Association class (WMD = −0.223, 95% CI: −0.781 to 0.335, <i>p</i> = 0.434, <i>I</i><sup>2</sup> = 87.1%). However, it effectively improved the status of thiamine deficiency (TD).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Our meta-analysis indicates that thiamine supplementation does not have a direct therapeutic effect on CHF, except for correcting TD.</p>\\n </section>\\n </div>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212003/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/clc.24309\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clc.24309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

摘要

背景：慢性心力衰竭（CHF慢性心力衰竭（CHF）一直对人类的生存和健康构成重大威胁。对慢性心力衰竭患者补充硫胺素的疗效仍不确定：假设：补充硫胺素可能不会给慢性心力衰竭患者带来益处：截至 2023 年 5 月，我们在 Cochrane Library、PubMed、EMBASE、ClinicalTrials.gov 和 Web of Science 数据库中进行了全面检索，以确定研究 CHF 患者补充硫胺素效果的文章。在选择研究特点和结果的数据时采用了预定义的标准：共纳入了七项随机、双盲、对照试验（五项平行试验和两项交叉试验），涉及 274 名患者。汇总这些研究的荟萃分析结果显示，与安慰剂相比，硫胺素治疗对左心室射血分数（WMD = 1.653%，95% CI：-1.098 至 4.405，p = 0.239，I2 = 61.8%）、左心室舒张末期容积（WMD = -6.831 mL，95% CI：-26.367 至 12.704，p = 0.493，I2 = 0.0%）、6 分钟步行试验（WMD = 16.526 m，95% CI：-36.582 至 69.634，p = 0.542，I2 = 66.3%）、N 末端前 B 型钠尿肽（WMD = 258.150 pg/mL，95% CI：-236.406 to 752.707，p = 0.306，I2 = 21.6%）或纽约心脏协会分级（WMD = -0.223，95% CI：-0.781 to 0.335，p = 0.434，I2 = 87.1%）。然而，它能有效改善硫胺素缺乏症（TD）的状况：我们的荟萃分析表明，除了纠正硫胺素缺乏症（TD）外，补充硫胺素对 CHF 没有直接的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Role of Thiamine Supplementation in the Treatment of Chronic Heart Failure: An Updated Meta-Analysis of Randomized Controlled Trials

Background

Chronic heart failure (CHF) has always posed a significant threat to human survival and health. The efficacy of thiamine supplementation in CHF patients remains uncertain.

Hypothesis

Receiving supplementary thiamine may not confer benefits to patients with CHF.

Methods

A comprehensive search was conducted across the Cochrane Library, PubMed, EMBASE, ClinicalTrials.gov, and Web of Science databases up until May 2023 to identify articles investigating the effects of thiamine supplementation in CHF patients. Predefined criteria were utilized for selecting data on study characteristics and results.

Results

Seven randomized, double-blind, controlled trials (five parallel trials and two crossover trials) involving a total of 274 patients were enrolled. The results of the meta-analysis pooling these studies did not reveal any significant effect of thiamine treatment compared with placebo on left ventricular ejection fraction (WMD = 1.653%, 95% CI: −1.098 to 4.405, p = 0.239, I² = 61.8%), left ventricular end-diastolic volume (WMD = −6.831 mL, 95% CI: −26.367 to 12.704, p = 0.493, I² = 0.0%), 6-min walking test (WMD = 16.526 m, 95% CI: −36.582 to 69.634, p = 0.542, I² = 66.3%), N-terminal pro-B type natriuretic peptide (WMD = 258.150 pg/mL, 95% CI: −236.406 to 752.707, p = 0.306, I² = 21.6%), or New York Heart Association class (WMD = −0.223, 95% CI: −0.781 to 0.335, p = 0.434, I² = 87.1%). However, it effectively improved the status of thiamine deficiency (TD).